Evidence map›Paper›PMID 25863129›Full record

ArticleCarcinogenesis2015

Tumor expression of adiponectin receptor 2 and lethal prostate cancer.

Jennifer R Rider, Michelangelo Fiorentino, Rachel Kelly, Travis Gerke, Kristina Jordahl, Jennifer A Sinnott, Edward L Giovannucci, Massimo Loda, Lorelei A Mucci, Stephen Finn and 1 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Carcinogenesis, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 31 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Adiponectin: Role in Physiology and Pathophysiology.International journal of preventive medicine · 2020
    Review
  8. Article
  9. Adipose Tissue, Obesity and Adiponectin: Role in Endocrine Cancer Risk.International journal of molecular sciences · 2019
    Review
  10. Low Expression of the Androgen-Induced Tumor Suppressor GeneCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2019
    Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Role of Adiponectin in prostate cancer.International braz j urol : official journal of the Brazilian Society of Urology
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 2 countries.

Jennifer R RiderChanning Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA, rider@hsph.harvard.edu.
Michelangelo FiorentinoPathology Unit, Addarii Institute of Oncology, S. Orsola-Malphighi Hospital, 40126 Bologna, Italy.
Rachel KellyChanning Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA, Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA, Pathology Unit, Addarii Institute of Oncology, S. Orsola-Malphighi Hospital, 40126 Bologna, Italy, Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA, Department of Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA and Department of Pathology, Trinity College Dublin, Dublin 8, Ireland.
Travis GerkeChanning Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA, Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA, Pathology Unit, Addarii Institute of Oncology, S. Orsola-Malphighi Hospital, 40126 Bologna, Italy, Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA, Department of Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA and Department of Pathology, Trinity College Dublin, Dublin 8, Ireland.
Kristina JordahlChanning Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA, Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA, Pathology Unit, Addarii Institute of Oncology, S. Orsola-Malphighi Hospital, 40126 Bologna, Italy, Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA, Department of Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA and Department of Pathology, Trinity College Dublin, Dublin 8, Ireland.
Jennifer A SinnottChanning Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA, Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA, Pathology Unit, Addarii Institute of Oncology, S. Orsola-Malphighi Hospital, 40126 Bologna, Italy, Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA, Department of Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA and Department of Pathology, Trinity College Dublin, Dublin 8, Ireland.
Edward L GiovannucciChanning Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA, Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA.
Massimo LodaDepartment of Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA and.
Lorelei A MucciChanning Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.
Stephen FinnDepartment of Pathology, Trinity College Dublin, Dublin 8, Ireland.
Transdisciplinary Prostate Cancer Partnership (ToPCaP)
Harvard University · USTrinity College Dublin · IE

Funding

Validity of Diet and Activity Measures in WomenP01CA055075 · NCI · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI RIMM, ERIC B · 1991 to 2009
$41.8M
Tumor and Circulating Markers as Links Between Obesity and Lethal Prostate CanceP50CA090381 · NCI · DANA-FARBER CANCER INSTITUTE · PI KANTOFF, PHILIP W · 2002 to 2017
$36.2M
Training Program in Cancer EpidemiologyT32CA009001 · NCI · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI A. Heather Eliassen, Meir Stampfer · 1985 to 2026
$17.3M
Physicians' Health Study II: Prevention Trial of VitaminsR01CA097193 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI GAZIANO, J. MICHAEL · 2002 to 2011
$15.7M
Statistical Methods for Analysis of Massive Genetic and Genomic Data in Cancer ResearchR35CA197449 · NCI · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI XIHONG LIN · 2015 to 2026
$10.9M
Joint Interdisciplinary Training Program in Biostatistics & Computational BiologyT32GM074897 · NIGMS · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI HUTTENHOWER, CURTIS, LIN, XIHONG · 2005 to 2019
$3.7M
Growth Factors and Lethal Prostate Cancer SignatureR01CA141298 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI STAMPFER, MEIR · 2010 to 2013
$2.2M
RANDOMIZED TRIAL OF ASPIRIN AND MORTALITYR01CA040360 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI BURING, JULIE E · 1985 to 2002
$775k
TRIAL OF ASPIRIN AND BETA-CAROTENE IN U S MD'SR01HL034595 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI BURING, JULIE E · 1985 to 1991
–
NCI NIH HHS 5P50CA090381-08NCI NIH HHS CA-097193NCI NIH HHS CA13389NCI NIH HHS CA141298NCI NIH HHS CA-34944NCI NIH HHS CA-40360NCI NIH HHS CA55075NCI NIH HHS P01 CA055075NCI NIH HHS P50 CA090381NCI NIH HHS R01 CA034944NCI NIH HHS R01 CA040360NCI NIH HHS R01 CA097193NCI NIH HHS R01 CA141298NCI NIH HHS R35 CA197449NCI NIH HHS T32 CA009001NHLBI NIH HHS HL-34595NHLBI NIH HHS R01 HL026490NHLBI NIH HHS R01 HL034595NIGMS NIH HHS T32 GM074897PHS HHS P0126490
6 · The paper itself

Abstract

To investigate the role of adiponectin receptor 2 (AdipoR2) in aggressive prostate cancer we used immunohistochemistry to characterize AdipoR2 protein expression in tumor tissue for 866 men with prostate cancer from the Physicians' Health Study and the Health Professionals Follow-up Study. AdipoR2 tumor expression was not associated with measures of obesity, pathological tumor stage or prostate-specific antigen (PSA) at diagnosis. However, AdipoR2 expression was positively associated with proliferation as measured by Ki-67 expression quartiles (P-trend < 0.0001), with expression of fatty acid synthase (P-trend = 0.001), and with two measures of angiogenesis (P-trend < 0.1). An inverse association was observed with apoptosis as assessed by the TUNEL assay (P-trend = 0.006). Using Cox proportional hazards regression and controlling for age at diagnosis, Gleason score, year of diagnosis category, cohort and baseline BMI, we identified a statistically significant trend for the association between quartile of AdipoR2 expression and lethal prostate cancer (P-trend = 0.02). The hazard ratio for lethal prostate cancer for the two highest quartiles, as compared to the two lowest quartiles, of AdipoR2 expression was 1.9 (95% confidence interval [CI]: 1.2-3.0). Results were similar when additionally controlling for categories of PSA at diagnosis and Ki-67 expression quartiles. These results strengthen the evidence for the role of AdipoR2 in prostate cancer progression.

Indexed as

AdiponectinAdultAgedAged, 80 and overApoptosisBiomarkers, TumorCell ProliferationDisease ProgressionFatty Acid Synthase, Type IHumansKi-67 AntigenMaleMiddle AgedNeovascularization, PathologicObesityProspective StudiesAdiponectinADIPOR2 protein, humanBiomarkers, TumorFASN protein, humanFatty Acid Synthase, Type IKi-67 AntigenProstate-Specific AntigenReceptors, Adiponectin

Identifiers

PMID25863129
PMCPMC4481603
OpenAlexW2015840430

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.